Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PDC-1421 in Adult ADHD Part I
NCT02699086Phase 2Completed
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of PDC-1421 in attention deficit hyperactivity disorder (ADHD) (2 arms). Primary endpoint: Number of Participants With Improvement ≥ 40% in ADHD-RS-IV From Baseline at 8 weeks. Started Dec 2019; status: completed.
02
Drugs
PDC-1421
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT02699086.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699086.